Lancet: Maintaining low-dose glucocorticoid therapy is more effective in controlling symptoms in patients with low-disease activity, rheumatoid arthritis.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!---- rheumatoid arthritis can have multiple adverse effects due to the long-term use of glucocorticoid drugs, and researchers recently examined the therapeutic effects of a gradual lysis of oral glucocorticoids on rheumatoid arthritis.SEMIRA study, adult patients with rheumatoid arthritis received 5-15 mg of toluride monotorthylaxis each day, using a small dose of glucocorticoids (polynisson 5 mg), lasting more than 24 weeks, and in a stable low disease activity state, 4-6 weeks before the grouping and the same day, 28 joint disease activity score - red cell deposition rate (DAS28-ESR) does not exceed 3.2.the patients were randomly treated with a continuous penisone 5 mg/day for 24 weeks, or gradually reduced their dosage until the drug was discontinued at the 16th week.in a 24-week study, all patients were treated with tobead monotolinates (162 mg per week, or 8 mg/kg intravenously every 4 weeks). The main result ofstudy was differences in the changes in the average DAS28-ESR from the baseline check to the 24th week.259 patients participated in the study, with 77 per cent women participating.128 patients who received the maintenance-based persisone programme, the disease activity control was better than that of 131 patients who received the persisone reduction programme: the pernison reduction programme group from baseline examination to the 24th week, the estimated average change of DAS28-ESR was 0.54, and the pernison maintenance programme group was -0.08.the treatment of 99 patients in the persinisone maintenance group (defined as 24 weeks of low disease activity, no rheumatoid arthritis attacks at 24 weeks, no confirmed adrenal insufficiency), and 85 patients in the pernel reduction group (relative risk 0.83).7 patients in the pertinisone reduction group had severe adverse events, 4 patients in the persinison maintenance group (5 vs. 3%), and no patients developed symptomatic adrenal insufficiency.study concluded that for people with rheumatoid arthritis who achieved low disease activity with torotheliosandinatinandanda and at least 24 weeks of glucocorticoid therapy, maintaining 5mg of glucocorticoids per day was better than the gradual reduction of glucocorticoids treatment..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.